WallStSmart

Iradimed Co (IRMD)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 42237% more annual revenue ($35.48B vs $83.81M). IRMD leads profitability with a 26.8% profit margin vs 13.0%. MDT appears more attractively valued with a PEG of 1.50. IRMD earns a higher WallStSmart Score of 60/100 (C).

IRMD

Buy

60

out of 100

Grade: C

Growth: 8.0Profit: 9.5Value: 2.0Quality: 5.0

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IRMDSignificantly Overvalued (-26.7%)

Margin of Safety

-26.7%

Fair Value

$81.34

Current Price

$101.78

$20.44 premium

UndervaluedFair: $81.34Overvalued
MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IRMD5 strengths · Avg: 8.8/10
Operating MarginProfitability
31.3%10/10

Strong operational efficiency at 31.3%

Return on EquityProfitability
24.8%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
26.8%9/10

Keeps 27 of every $100 in revenue as profit

Revenue GrowthGrowth
17.0%8/10

17.0% revenue growth

EPS GrowthGrowth
24.8%8/10

Earnings expanding 24.8% YoY

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

IRMD4 concerns · Avg: 2.8/10
Price/BookValuation
13.8x4/10

Trading at 13.8x book value

Market CapQuality
$1.30B3/10

Smaller company, higher risk/reward

PEG RatioValuation
4.462/10

Expensive relative to growth rate

P/E RatioValuation
58.2x2/10

Premium valuation, high expectations priced in

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : IRMD

The strongest argument for IRMD centers on Operating Margin, Return on Equity, Profit Margin. Profitability is solid with margins at 26.8% and operating margin at 31.3%. Revenue growth of 17.0% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : IRMD

The primary concerns for IRMD are Price/Book, Market Cap, PEG Ratio. A P/E of 58.2x leaves little room for execution misses.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

IRMD profiles as a growth stock while MDT is a value play — different risk/reward profiles.

IRMD carries more volatility with a beta of 1.10 — expect wider price swings.

IRMD is growing revenue faster at 17.0% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

IRMD scores higher overall (60/100 vs 56/100), backed by strong 26.8% margins and 17.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Iradimed Co

HEALTHCARE · MEDICAL DEVICES · USA

IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?